AMJEVITA™ (ADALIMUMAB-ATTO), FIRST BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Amgen launches an AbbVie Humira biosimilar in the US
January 31, 2023 1:56 PM ESTAfter a dip earlier in the session, AbbVie (NYSE: ABBV) shares are now slightly up on the day, holding steady, despite Amgen (NASDAQ: AMGN) announcing AMJEVITA, a biosimilar to Humira, is now available in the United States.
AMJEVITA was the first biosimilar to AbbVie's Humira approved by the U.S. Food and Drug Administration and is now available in the U.S. at a list price 5% below the current Humira list... More
